{"title":"Considering IL-6","authors":"I. McInnes","doi":"10.1136/CONMED-2018-000006","DOIUrl":null,"url":null,"abstract":"Targeting interleukin (IL)−6 or its receptor for the treatment of inflammatory disease is an attractive approach to the management of complex inflammatory diseases, especially those with a systemic component to their presentation and comorbidity. Biological drugs that target IL-6 receptor are already in clinical practice. Recently, more agents are emerging from clinical trials that block distinct parts of the IL-6/IL-6R pathway.\n\nIn this edition, Jones et al explore the rich diversity of biology mediated by IL-6. …","PeriodicalId":356175,"journal":{"name":"Considerations in Medicine","volume":"19 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Considerations in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/CONMED-2018-000006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Targeting interleukin (IL)−6 or its receptor for the treatment of inflammatory disease is an attractive approach to the management of complex inflammatory diseases, especially those with a systemic component to their presentation and comorbidity. Biological drugs that target IL-6 receptor are already in clinical practice. Recently, more agents are emerging from clinical trials that block distinct parts of the IL-6/IL-6R pathway.
In this edition, Jones et al explore the rich diversity of biology mediated by IL-6. …
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
